After successful hepatitis C virus antiviral therapy: It looks that normal alanine aminotransferase level is not the normal

Kassas, Mohamed El; Alboraie, Mohamed; Mostafa, Aya; Ezzat, Reem; Tahan, Adel El; Afify, Shimaa; Sweedy, Ahmed; Kabbash, Ibrahim Ali; Esmat, Gamal

doi:10.1002/jcla.22296

Cited by 6 publications

(5 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study found similar results in Portuguese patients with advanced liver disease (19) . However, our findings disagree with those of another Egyptian study where, greater improvement in ALT levels was shown to be associated with the absence of advanced fibrosis/cirrhosis (20) .…”

Section: Discussioncontrasting

confidence: 99%

Long-term Follow-up of Chronic Hepatitis C Patients Treated by Direct- Acting Antivirals

Tawheed¹,

Kassas²,

Elfouly³

et al. 2023

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Hepatitis C virus HCV infection is one of the main causes of chronic liver disease worldwide, Egypt has the highest national-level HCV prevalence in the world, and direct Acting Antivirals are widely used to treat HCV infection in Egypt. Aim: To perform a long-term follow-up of patients with chronic hepatitis C who received IFN free regimen of directacting antivirals (DAAs). The follow-up aimed to study the incidence of hepatocellular carcinoma, viral recurrence in this cohort of patients and improvement of liver biochemicals or liver decompensation. Methodology: We recruited 1041 Egyptian HCV patients, who finished treatment more than 1 year before recruitment and then we assessed the improvement of the biochemical profile and the liver condition, incidence of occurrence or recurrence hepatocellular carcinoma after treatment. Results: The follow-up values of ALT, AST, INR, Bilirubin, Platelets and fibrosis-4 (Fib-4) showed a statistically significant improvement more than 1 year after treatment, while the improvement in albumin and AFP was noted without statistical significancy. By comparing the different groups of the study, patients with advanced liver disease showed a greater improvement in those parameters. However, they carried an increased risk of developing hepatocellular carcinoma. Conclusion: Achieving SVR using DAAs can improve liver functions tests, AFP, platelet count and FIB-4 value and persons with severe liver disease should be advised to undergo HCC surveillance after achieving sustained virological response (SVR).

show abstract

Section: Discussioncontrasting

confidence: 99%

Long-term Follow-up of Chronic Hepatitis C Patients Treated by Direct- Acting Antivirals

Tawheed¹,

Kassas²,

Elfouly³

et al. 2023

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

show abstract

“…Males below 50 years, Males above 50 years old, Females below 50 years old, and females above 50 years, and it was confirmed significant decreases to normal levels of ALT and AST in these different groups. This result is consistent with previous studies (El Kassas et al, 2018;Abdel-Aziz et al, 2018;Ali et al, 2020). Sofosbuvir and Daclatasvir are highly effective combinations for treating hepatitis C virus infections Bhatia et al, 2014;Sulkowski et al, 2014;Poordad et al, 2019;Lionetti et al, 2019;Ahmed et al, 2018).…”

Section: Discussionsupporting

confidence: 93%

“…Accordingly, several factors that may affect the integrity of hepatocytes should influence the concentration of liver enzymes. However, a continuously elevated ALT for more than six months is used as a diagnostic reason for chronic hepatitis (El Kassas et al, 2018). High ALT levels or other biochemical marker abnormalities such as ALT, AST, ALP, total Protein & Albumin, and total and direct bilirubin are associated with hepatitis C infection (David et al, 2007).…”

Section: Discussionmentioning

confidence: 99%

“…In acute or chronic viral hepatitis, hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are among the major causes of elevated ALT and AST levels. The average upper normal limits (ULN) for ALT in blood donors with non-B non-C hepatitis ranged from 40 to 50 Unit/L (El Kassas et al, 2018) and the normal upper limits for AST are up to 40 Unit/L (Huang et al, 2006).…”

Section: Alt and Ast Featuresmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of Patients' Recovery from Hepatitis C Following Antiviral Treatment with Daclatasvir and Sofosbuvir in AL-Baha Region

Alghamdi,

Mohammed

2024

International Journal of Advanced Humanities Research

View full text Add to dashboard Cite

show abstract

“…Consistent with our results, several investigations found that hepatic transaminase levels dropped significantly after SVR in response to DAAs (16) . Also El Kassas et al (17) who examined the effect of DAA therapy on ALT levels in 1160 patients with chronic hepatitis C Liver enzymes were observed to be significantly reduced in Egyptian individuals treated with interferon-free regimens compared to those treated with interferon-containing regimens. In contrast, Russo et al (18) which studied the effect of HCV eradication with DAA on insulin resistance found no difference between pretreatment and post treatment level of AST and ALT.…”

Section: Discussionmentioning

confidence: 99%

Impact of Direct Acting Antivirals Therapy on Novel Fibrosis Index for Assessment of Hepatic Fibrosis in Comparison with AST to Platelet Ratio and Fibrosis-4 (FIB-4) Indexes in Egyptian Patients with Chronic Hepatitis C Infection in Correlation with Fibroscan

Allam

El-Karmouty

Kaisar

et al. 2023

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Scarring or progressive fibrosis and cirrhosis develop over time as a result of chronic viral infection, which induces inflammation and tissue healing via deposition of extracellular matrix. There has been an increase in the sustained virological response (SVR) and the rate of eradication of HCV because of the effectiveness of directacting antiviral drugs (DAAs). Reduced hepatic fibrosis is associated with increased SVR rates. There are a variety of non-invasive fibrosis imaging, scoring, and marker methods: transient elastography, aminotransferase platelet ratio index (APRI), as well as fibrosis-4 (FIB-4) score. Objective: The purpose of this research was comparing the novel fibrosis index to APRI, (FIB-4) score and fibroscan in predicting the degree of hepatic fibrosis in Egyptian chronic HCV patients who were managed by DAAs. Patients and methods: 100 Egyptians with chronic HCV infection participated in a our 3-month long prospective Cohort research using the IFN-free DAA combination of Sofosbuvir and Daclatasvir ± Ribavirin. Results: There was significant regression of fibrosis with DAAs treatment in all patients achieving SVR by fibroscan, APRI and fib4. Novel fibrosis index is reliable and good tool in estimation of liver fibrosis in correlation to fibroscan, with the cutoff value in prediction of hepatic fibrosis stage 4 was >3.1 and has sensitivity of 81.5% while the specificity was 74.1%. Conclusion Novel fibrosis index has been found to be good reliable marker for assessment of liver fibrosis with high accuracy of predicting f4 fibrosis stage. There was significant marked reduction of fibrosis degree by fibroscan, APRI and FIB4 after DAAs treatment.

show abstract

After successful hepatitis C virus antiviral therapy: It looks that normal alanine aminotransferase level is not the normal

Abstract: The current ALT ULN needs readjustment to identify new normal cutoffs in CHC patients. Posttreatment cutoffs differ according to gender, pretreatment liver affection, and treatment regimen.

Cited by 6 publications

References 37 publications

Long-term Follow-up of Chronic Hepatitis C Patients Treated by Direct- Acting Antivirals

Long-term Follow-up of Chronic Hepatitis C Patients Treated by Direct- Acting Antivirals

Evaluation of Patients' Recovery from Hepatitis C Following Antiviral Treatment with Daclatasvir and Sofosbuvir in AL-Baha Region

Impact of Direct Acting Antivirals Therapy on Novel Fibrosis Index for Assessment of Hepatic Fibrosis in Comparison with AST to Platelet Ratio and Fibrosis-4 (FIB-4) Indexes in Egyptian Patients with Chronic Hepatitis C Infection in Correlation with Fibroscan

Contact Info

Product

Resources

About